

FX Weekly

Fade Fears of Omicron and Fed

The Week Ahead

- **Dollar Index - Fade.** Support at 94.50; Resistance at 97.70
- **USD/SGD - Hanging Man.** Support at 1.3550; Resistance at 1.3750
- **USD/MYR - Correction.** Support at 4.1890; Resistance at 4.2500
- **AUD/SGD - Downside Risk.** Support at 0.9535; Resistance at 0.9920
- **SGD/MYR - Downside.** Support at 3.0720; Resistance at 3.1050

Interim USD Strength but Watch US Payrolls (830pm SG/MY time)

An uneasy confluence of omicron variant concerns and potential Fed policy shifts saw volatilities rise across multi asset classes, including equities, bonds, oil and FX. Omicron's spread and high transmissibility characteristics have lived up to its reputation. More cases of the variant has been found across the world including US, India, Korea, Singapore. This raises concerns of the potential for tighter border controls globally and is a setback to reopening momentum. We maintained our view that uncertainty on Omicron will drive markets both ways and it will take up to weeks for health experts to tell the impact variant has on vaccines. However it not likely we return back to a year ago as (1) more people are vaccinated today than a year ago and; (2) vaccine technology has advanced tremendously. There are now more variety of vaccines and treatment drugs than a year ago. Just before we wrap up the choppy week, we watch US payrolls tonight (830pm SG/MY time). Consensus is looking for NFP to pick up slightly to +550k (vs. +531k prior), unemployment rate to improve further to 4.5%, down from 4.6% and for hourly earnings to pick up to 5%. A stronger than expected or in-line with expectations report could keep USD supported but a much weaker report could upset USD bulls. For USDSGD, bias to fade rallies towards 1.3750 for a move lower towards 1.3550 while we look for a corrective move lower in USD below 4.20.

Fed Paving the Ground for Hawkish Shift at Next FoMC

Fed speaks this week gave the impression that Fed is potentially preparing the ground for a hawkish shift at upcoming FoMC (15-16 Dec) even with uncertainties around omicron variant. In particular Fed Chair Powell told senate banking panel that "it's probably a good time to retire the word, transitory" and that Fed is prepared to quicken the pace of tapering. Quarles said it was time for Fed to prepare to raise interest rates because inflation was likely to stay above Fed's 2% target for longer than anticipated and he also said that this is not a bottleneck story anymore and the Fed needs to bring supply and demand into balance by raising rates to cool the economy until businesses create more productive capacity to meet higher levels of demand. We opined it is likely that pace of taper could step up to end by 1Q-2022 instead of Jun-2022 and that 2 hikes may form Fed's baseline (up from 1 previously). This could add to front-loading of USD strength.

RBA; EU ZEW and CPIs from US, Germany, China Next Week

Some of the data we watch next week include UK construction PMI on Mon. For Tue, US trade; EU ZEW, 3Q GDP; RBA policy decision - expect policy status quo. For Wed, US JOLTS job openings, Japan GDP. For Thu, NX mfg activity; China CPI, PPI. For Fri, US CPI; German CPI; NZ mfg PMI; UK data dump; Malaysia IP.

Analysts

Saktiandi Supaat
(65) 6320 1379
saktiandi@maybank.com.sg

Christopher Wong
(65) 6320 1347
wongkl@maybank.com.sg

Fiona Lim
(65) 6320 1374
fionalim@maybank.com.sg

Tan Yanxi
(65) 6320 1378
tanyx@maybank.com.sg

Our in-house model implies that S\$NEER is trading at +0.46% to the implied midpoint of 1.3762, suggesting that it is firmer vs. other trading partner currencies.

Bloomberg FX Ranking

1Q 2021












No. 2 for SGD, CNH
No. 3 for NZD, THB
No. 5 for AUD

2Q 2021

No. 2 for CNH
No. 3 for TWD, SGD, CAD
No. 5 for CNY
No. 10 for GBP

3Q 2021

No. 1 for VND
No. 3 for TWD

Currency	Direction	Support/Resistance	Key Data and Events
Dollar Index		S: 94.50; R: 97.70	Mon: - Nil - Tue: Trade (Oct); Wed: JOLTS Job openings (Oct); Thu: Wholesale trade sales, inventories (Oct); Fri: CPI (Nov); Uni of Michigan sentiment (Dec P)
EURUSD		S: 1.1200; R: 1.1420	Mon: Sentix investor confidence (Dec); German factory orders (Oct) Tue: GDP, Employment (3Q); ZEW survey expectations (Dec); Wed: - Nil - Thu: German trade (Oct) Fri: German CPI (Nov)
AUDUSD		S: 0.7050; R: 0.7240	Mon: - Nil - Tue: RBA Policy decision; House price index (3Q); FX Reserves (Nov) Wed: - Nil - Thu: - Nil - Fri: - Nil -
NZDUSD		S: 0.6710; R: 0.6960	Mon: ANZ Commodity price (Nov); Tue: - Nil - Wed: - Nil - Thu: Mfg activity (3Q) Fri: Mfg PMI, card spending (Nov)
GBPUSD		S: 1.3240; R: 1.3520	Mon: Construction PMI (Nov); Tue: - Nil - Wed: - Nil - Thu: - Nil - Fri: Monthly GDP, IP, Trade, construction output, Trade (Oct)
USDJPY		S: 112.50; R: 114.00	Mon: - Nil - Tue: Leading index (Oct P); Wed: GDP (3Q); Current account (Oct) Thu: BSI Large All industry (4Q); machine tool orders (Nov P); Fri: PPI (Nov)
USDCNH		S: 6.3500; R: 6.4200	Mon: - Nil - Tue: Trade, FX Reserves (Nov); Wed: - Nil - Thu: CPI, PPI (Nov) Fri: - Nil -
USDSGD		S: 1.3550; R: 1.3750	Mon: - Nil - Tue: FX Reserves (Nov); Wed: - Nil - Thu: - Nil - Fri: - Nil -
USDMYR		S: 4.1890; R: 4.2500	Mon: - Nil - Tue: FX Reserves (Nov); Wed: - Nil - Thu: - Nil - Fri: Industrial production (Oct)
USDPHP		S: 49.80; R: 50.70	Mon: - Nil - Tue: CPI (Nov); Unemployment (Oct); Wed: - Nil - Thu: - Nil - Fri: Trade (oct)
USDIDR		S: 14,250; R: 14,500	Mon: - Nil - Tue: FX Reserves (Nov); Wed: Consumer confidence (Nov) Thu: - Nil - Fri: - Nil -

Sources: Bloomberg, Maybank FX Research & Strategy

Selected G7 FX Views

Currency	Stories of the Week
DXY Index	<p>Fed Shifts. An uneasy confluence of omicron variant concerns and potential Fed policy shifts saw volatilities rise across multi asset classes, including equities, bonds, oil and FX. Omicron's spread and high transmissibility characteristics have lived up to its reputation. More cases of the variant has been found across US and now, India and Singapore announced first cases overnight. This raises concerns of the potential for tighter border controls globally and is a setback to reopening momentum. We maintained our view that uncertainty on Omicron will drive markets both ways and it will take up to weeks for experts to tell the impact variant has on vaccines. However it not likely we return back to a year ago as (1) more people are vaccinated today than a year ago and; (2) vaccine technology has advanced tremendously. There are now more variety of vaccines and treatment drugs than a year ago. Just before we wrap up the choppy week, we watch US payrolls tonight (830pm SG/MY time). Consensus is looking for NFP to pick up slightly to +550k (vs. +531k prior), unemployment rate to improve further to 4.5%, down from 4.6% and for hourly earnings to pick up to 5%. A stronger than expected or in-line with expectations report could keep USD supported but a much weaker report could upset USD bulls.</p> <p>Fed speaks this week gave the impression that Fed is potentially preparing the ground for a hawkish shift at upcoming FoMC (15-16 Dec) even with uncertainties around omicron variant. In particular Fed Chair Powell told senate banking panel that "its probably a good time to retire the word, transitory" and that Fed is prepared to quicken the pace of tapering. Bostic said that "it would be in our interest" to end QE purchases towards end-1Q to give it more flexibility to raise rates if needed. He added there is a good case to pull forward more rate hikes if inflection is elevated in 2022 but his preferred path is to go slow and steady. Daly said that she expects more than 1 hike pencilled in the dots plot at the upcoming FoMC (15-16 Dec). Outgoing Quarles said it was time for Fed to prepare to raise interest rates because inflation was likely to stay above Fed's 2% target for longer than anticipated and he also said that this is not a bottleneck story anymore and the Fed needs to bring supply and demand into balance by raising rates to cool the economy until businesses create more productive capacity to meet higher levels of demand. We opined it is likely that pace of taper could step up to end by 1Q-2022 instead of Jun-2022 and that 2 hikes may form Fed's baseline (up from 1 previously). This could add to front-loading of USD strength.</p> <p>DXY was last at 96.22 levels. Mild bearish momentum on daily chart while decline in RSI moderated for now. We are biased to lean against strength. Resistance at 96.70, 97.70 (61.8% fibo). Support next at 95.5 (21 DMA) before 94.40/50 (38.2% fibo retracement of 2020 high to 2021 low, 50 DMA).</p> <p><i>Next week brings Trade (Oct) on Tue; JOLTS Job openings (Oct) on Wed; Wholesale trade sales, inventories (Oct) on Thu; CPI (Nov); Uni of Michigan sentiment (Dec P) on Fri.</i></p>
EUR/USD	<p>Downside Risk. EUR was caught between a rock and a hard place. On one hand, widening yield differentials amid ECB-Fed policy divergence weighed on EUR but on the other hand, its "safe haven" characteristic is supportive of EUR (as markets unwind carry trades funded by negative yielders such as EUR, JPY, CHF).</p> <p>This week there were reports saying that a growing number of ECB officials were considering delaying decision on post-PEPP plan. The ECB has earlier indicated that they will provide an update at the 16th Dec ECB meeting with regards to asset purchases plans after PEPP lapsed in Mar-2022. Chatters were for this to be pushed out to 3rd Feb meeting when more details and impact on omicron variant comes to light. A delay in decision (if any) would come in sharp contrast to the Fed, whom has been talking about faster pace of tapering even with omicron variant. This divergence in monetary policy bias exposes EUR's vulnerability as further widening in yield differentials may drag on EUR.</p> <p>EUR was last at 1.1295 levels. Daily momentum turned mild bullish while rise in RSI moderated. Sideways trade likely. Resistance at 1.1360 (21 DMA) and 1.1490 levels (50% fibo retracement of 2020 low to 2021 high). Support at 1.1290 (61.8% fibo), 1.1220, 1.1180.</p> <p><i>Next week brings Sentix investor confidence (Dec); German factory orders (Oct) on Mon; GDP, Employment (3Q); ZEW survey expectations (Dec) on Tue; German trade (Oct) on Thu and German CPI (Nov) on Fri.</i></p>
GBP/USD	<p>Looking for Technical Rebound. GBP continued to trade near recent lows this week amid omicron</p>

uncertainty, Fed (potentially quickening its pace of policy normalisation) while markets pared back expectations of a Dec BoE hike. UK had warned that people should not assume that covid will evolve to become a milder disease while the New and emerging respiratory virus threats advisory group urged UK ministers to take early and robust actions to limit transmission of omicron variant. Worries of pre-emptive measures taken by policymakers to tighten restrictions would dampen reopening momentum and weighed on risk sentiments, including GBP. That said we refrain from jumping the gun on omicron negatives as experts said that it remains too early to tell the impact of omicron on vaccines. Furthermore UK has also recently approved the use of an antibody treatment, sotrovimab which the manufacturers said appear to be effective against the omicron variant.

Pair was last at 1.3290. Bearish momentum on daily chart still intact while RSI is near oversold conditions. Potential bullish divergence still seen on daily MACD - yet to play out. Falling wedge pattern observed - a potential bullish reversal. We monitor price actions for potential rebound. Resistance at 1.3350, 1.3410 (23.6% fibo retracement of Oct high to Nov low), 1.3460 (50 DMA). Support here at 1.3280, 1.3190 (2021 low).

Relatively quiet week ahead with Construction PMI (Nov) on Mon and a data dump on Fri: Monthly GDP, IP, Trade, construction output, Trade (Oct).

USD/JPY **Risks to the Upside.** USDJPY fell to a low of 112.53 (Tue) before erasing losses. Fed speaks this week suggest a potential hawkish shift. Repricing of hawkish shift adds to higher near term yields and this could drive USDJPY higher in the interim. 2y UST yield rose from 0.49% at start of week to 0.62%.

Pair was last seen at 113.45 levels. Mild bearish momentum shows signs of fading while RSI is rising from near overbought conditions. Risks to the downside. Resistance at 114 (21 DMA), 115, 115.5. Support at 113.10 (50 DMA), 112.50 levels.

Next week brings Leading index (Oct P) on Tue; GDP (3Q); Current account (Oct) on Tue; BSI Large All industry (4Q); machine tool orders (Nov P) on Thu; PPI (Nov) or Fri.

AUD/USD **RBA on Hold.** AUD traded lower this week amid Fed's hawkish speaks and omicron uncertainty. Pair was last at 0.7060 levels. Bearish momentum on daily chart intact while RSI dips into oversold conditions. Bias to the downside. Next support at 0.7050 and 0.70 levels. Resistance at 0.7105, 0.7240 levels (2 DMA). RBA policy decision is due next Tue - we expect policy status quo given little evidence of wage increase while core inflation has barely only made its way into the target band for the first time in a long while. We expect RBA to lag other G7 central banks.






Next week brings RBA Policy decision; House price index (3Q); FX Reserves (Nov) on Tue.

NZD/USD **Oversold.** Break below double-bottom at 0.6810 is somewhat adding to bearish pressure this week. NZD was last seen at 0.67850 levels. Bearish momentum on daily chart shows tentative signs of fading while RSI is in oversold conditions. We are still biased to buy dips, opportunistically. Support at 0.6770 levels. Resistance at 0.6860, 0.6905 (23.6% fibo retracement of Oct high to Nov low), 0.6960 (32.8% fibo).

While caution is warranted on omicron variant, we see the glass half-full rather than half empty. We opined it not likely we return back to a year ago as (1) more people are vaccinated today than a year ago and; (2) vaccine technology has advanced tremendously. There are now more variety of vaccines and treatment drugs than a year ago. Moderna, Pfizer are saying that modified mRNA vaccine is possible within six weeks and that can ship initial batches within 100 days. Experts also pointed to the existence of antiviral drug such as Merck's covid pill (molnupiravir) and existing therapy via anti-inflammatory drug (dexamethasone) that are likely to work against omicron. Though a recent study found that omicron is at least 2.4x more likely to re-infect people who previously had covid, it also said that virus may be no more transmissible than delta and illness it causes is thought to be less severe.

Next week brings ANZ Commodity price (Nov) on Mon; Mfg activity (3Q) on Thu; Mfg PMI, card spending (Nov) on Fri.

Technical View: MYR Crosses

MYR Crosses	Direction	Support/Resistance	Stories of the Week
SGD/MYR		S: 3.0720; R: 3.1050	Slight Bias for Downside Play. SGDMYR consolidate in choppy fashion this week. Cross was last at 3.0855 levels. Mild bullish momentum on daily chart shows signs of fading while RSI shows signs of turning lower. We are slightly biased for renewed downside play. Support at 3.0830/40 (50DMA, 50% fibo), 3.0810 (21 DMA), 3.0720 (61.8% fibo). An extended move lower towards 3.0680 is not ruled out. Resistance at 3.0940/60 levels (100 DMA, 38.2% fibo retracement of Mar low to 2021 double top), 3.1050, 3.1110 (23.6% fibo).
AUD/MYR		S: 3.0000; R: 3.0700	Consolidation. AUDMYR slipped this week amid AUD underperformance. Cross was last seen at 3.0095 levels. Bearish momentum on daily chart intact while RSI rose from oversold conditions. Room for further consolidation. Support at 2.9950 (previous low), 2.99 levels. Resistance at 3.0250, 3.0350.
EUR/MYR		S: 4.7600; R: 4.8500	Rebound Underway. EURMYR extended its rebound this week, in line with our call - <i>looking for extended rebound</i> . Move higher came amid EUR strength while MYR fell sharply. Cross was last at 4.7930 levels. Bullish momentum intact while RSI is rising. Room for further upside. Immediate resistance at 4.8130 (50 DMA), 4.8490 levels. Support at 4.76, 4.7050 levels.
GBP/MYR		S: 5.6000; R: 5.6800	Trying to Find a Bottom. GBPMYR slipped this week. Cross was last seen at 5.6280 levels. Mild bullish momentum is fading while RSI climbed. Consolidative trades likely. Resistance at 5.6490 (23.6% fibo retracement of Jul high to Nov low), 5.6690 (50 DMA) and 5.7370 (100, 200 DMAs). Support at 5.60, 5.5650 levels (Nov low).
JPY/MYR		S: 3.7000; R: 3.7800	Retain Bias to Buy Dips. JPYMYR traded higher this week/ Cross was last at 3.7410. Bias still to buy dips. Support at 3.6540 (21 DMA), 3.6250 (2021 low). Resistance at 3.75, 3.78. Support at 3.7140, 3.6960 (50 DMA).

Technical Chart Picks:

USDSGD Weekly Chart - Hanging Man?



USDSGD fell in early week but partially reversed early week's losses into Fri session.

On daily chart (not shown here), bullish momentum is fading while RSI is falling. On weekly chart, we noted a potential hanging man candlestick (but note that trading session is still ongoing at time of writing and price swings can occur). If confirmed, this can signal an interim top is in place. We watch for confirmation in price action next week. Risk-reward favour a sell rallies (with tight stop placed 10-20pips above said-resistance).

Immediate resistance at 1.3730/50 (38.2% fibo retracement of 2020 high to 2021 low).

Support at 1.3605 (21 DMA), 1.3540/50 (50, 100 DMAs).

USDMYR Daily Chart - Chance for Corrective Move Lower



USDMYR consolidated near recent highs this week. Last seen at 4.2300 levels.

Bullish momentum on daily chart faded while RSI declined from overbought conditions. We are biased for corrective move lower.

Support at 4.2220 (50% fibo), 4.20 and 4.1890 (21, 100 DMAs). An extension of the pullback towards 4.1530 (200 DMA) is not ruled out.

Immediate resistance at 4.2450 (2021 high), 4.2760 (61.8% fibo retracement of 2020 high to 2021 low).

Note: blue line - 21SMA; red line - 50 SMA; green line - 100 SMA; yellow line - 200 SMA

AUDSGD Daily Chart: Break-Out but Caution for Snapback Risk



Our caution for AUDSGD to break out of its inverted cup and “handle” pattern came to fruition this week. Cross was last at 0.9690 levels.

Bearish momentum on daily chart intact while RSI is in oversold conditions. Inverted cup and handle pattern is in play - typically a bearish continuation pattern. Next support at 0.9673 (previous low in 2021). A decisive break below may see the cross extend its decline towards where the inverted cup and handle started at: 0.9535 levels (Oct-2020). One note of caution is that a falling wedge is developing. We caution for snapback risk ahead.

Resistance at 0.9770 (76.4% fibo retracement of Oct-2020 low to 2021 high), 0.9850 (21 DMA) and 0.9920 (21, 50 DMAs).

SGDMYR Daily Chart: Bias for Downside Play



SGDMYR consolidate in choppy fashion this week. Cross was last at 3.0855 levels.

Mild bullish momentum on daily chart shows signs of fading while RSI shows signs of turning lower. We are slightly biased for renewed downside play.

Support at 3.0830/40 (50DMA, 50% fibo), 3.0810 (21 DMA), 3.0720 (61.8% fibo). An extended move lower towards 3.0680 is not ruled out.

Resistance at 3.0940/60 levels (100 DMA, 38.2% fibo retracement of Mar low to 2021 double top), 3.1050, 3.1110 (23.6% fibo).

DISCLAIMER

This report is for information purposes only and under no circumstances is it to be considered or intended as an offer to sell or a solicitation of an offer to buy the securities or financial instruments referred to herein, or an offer or solicitation to any person to enter into any transaction or adopt any investment strategy. Investors should note that income from such securities or financial instruments, if any, may fluctuate and that each security's or financial instrument's price or value may rise or fall. Accordingly, investors may receive back less than originally invested. Past performance is not necessarily a guide to future performance. This report is not intended to provide personal investment advice and does not take into account the specific investment objectives, the financial situation and the particular needs of persons who may receive or read this report. Investors should therefore seek financial, legal and other advice regarding the appropriateness of investing in any securities and/or financial instruments or the investment strategies discussed or recommended in this report.

The information contained herein has been obtained from sources believed to be reliable but such sources have not been independently verified by Malayan Banking Berhad and/or its affiliates and related corporations (collectively, "Maybank") and consequently no representation is made as to the accuracy or completeness of this report by Maybank and it should not be relied upon as such. Accordingly, no liability can be accepted for any direct, indirect or consequential losses or damages that may arise from the use or reliance of this report. Maybank and its officers, directors, associates, connected parties and/or employees may from time to time have positions or be materially interested in the securities and/or financial instruments referred to herein and may further act as market maker or have assumed an underwriting commitment or deal with such securities and/or financial instruments and may also perform or seek to perform investment banking, advisory and other services for or relating to those companies whose securities are mentioned in this report. Any information or opinions or recommendations contained herein are subject to change at any time, without prior notice.

This report may contain forward looking statements which are often but not always identified by the use of words such as "anticipate", "believe", "estimate", "intend", "plan", "expect", "forecast", "predict" and "project" and statements that an event or result "may", "will", "can", "should", "could" or "might" occur or be achieved and other similar expressions. Such forward looking statements are based on assumptions made and information currently available to us and are subject to certain risks and uncertainties that could cause the actual results to differ materially from those expressed in any forward looking statements. Readers are cautioned not to place undue relevance on these forward looking statements. Maybank expressly disclaims any obligation to update or revise any such forward looking statements to reflect new information, events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

This report is prepared for the use of Maybank's clients and may not be reproduced, altered in any way, transmitted to, copied or distributed to any other party in whole or in part in any form or manner without the prior express written consent of Maybank. Maybank accepts no liability whatsoever for the actions of third parties in this respect. This report is not directed to or intended for distribution to or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.

Published by:



Malayan Banking Berhad
(Incorporated in Malaysia)

Saktiandi Supaat
Head, FX Research
saktiandi@maybank.com.sg
(+65) 63201379

Christopher Wong
Senior FX Strategist
wongkl@maybank.com.sg
(+65) 63201347

Fiona Lim
Senior FX Strategist
Fionalim@maybank.com.sg
(+65) 63201374

Yanxi Tan
FX Strategist
tanyx@maybank.com.sg
(+65) 63201378

APPENDIX I: TERMS FOR PROVISION OF REPORT, DISCLAIMERS AND DISCLOSURES

DISCLAIMERS

This research report is prepared for general circulation and for information purposes only and under no circumstances should it be considered or intended as an offer to sell or a solicitation of an offer to buy the securities referred to herein. Investors should note that values of such securities, if any, may fluctuate and that each security's price or value may rise or fall. Opinions or recommendations contained herein are in form of technical ratings and fundamental ratings. Technical ratings may differ from fundamental ratings as technical valuations apply different methodologies and are purely based on price and volume-related information extracted from the relevant jurisdiction's stock exchange in the equity analysis. Accordingly, investors' returns may be less than the original sum invested. Past performance is not necessarily a guide to future performance. This report is not intended to provide personal investment advice and does not take into account the specific investment objectives, the financial situation and the particular needs of persons who may receive or read this report. Investors should therefore seek financial, legal and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report.

The information contained herein has been obtained from sources believed to be reliable but such sources have not been independently verified by Maybank Investment Bank Berhad, its subsidiary and affiliates (collectively, "MKE") and consequently no representation is made as to the accuracy or completeness of this report by MKE and it should not be relied upon as such. Accordingly, MKE and its officers, directors, associates, connected parties and/or employees (collectively, "Representatives") shall not be liable for any direct, indirect or consequential losses or damages that may arise from the use or reliance of this report. Any information, opinions or recommendations contained herein are subject to change at any time, without prior notice.

This report may contain forward looking statements which are often but not always identified by the use of words such as "anticipate", "believe", "estimate", "intend", "plan", "expect", "forecast", "predict" and "project" and statements that an event or result "may", "will", "can", "should", "could" or "might" occur or be achieved and other similar expressions. Such forward looking statements are based on assumptions made and information currently available to us and are subject to certain risks and uncertainties that could cause the actual results to differ materially from those expressed in any forward looking statements. Readers are cautioned not to place undue relevance on these forward-looking statements. MKE expressly disclaims any obligation to update or revise any such forward looking statements to reflect new information, events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

MKE and its officers, directors and employees, including persons involved in the preparation or issuance of this report, may, to the extent permitted by law, from time to time participate or invest in financing transactions with the issuer(s) of the securities mentioned in this report, perform services for or solicit business from such issuers, and/or have a position or holding, or other material interest, or effect transactions, in such securities or options thereon, or other investments related thereto. In addition, it may make markets in the securities mentioned in the material presented in this report. One or more directors, officers and/or employees of MKE may be a director of the issuers of the securities mentioned in this report to the extent permitted by law.

This report is prepared for the use of MKE's clients and may not be reproduced, altered in any way, transmitted to, copied or distributed to any other party in whole or in part in any form or manner without the prior express written consent of MKE and MKE and its Representatives accepts no liability whatsoever for the actions of third parties in this respect.

This report is not directed to or intended for distribution to or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. This report is for distribution only under such circumstances as may be permitted by applicable law. The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Without prejudice to the foregoing, the reader is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

Malaysia

Opinions or recommendations contained herein are in the form of technical ratings and fundamental ratings. Technical ratings may differ from fundamental ratings as technical valuations apply different methodologies and are purely based on price and volume-related information extracted from Bursa Malaysia Securities Berhad in the equity analysis.

Singapore

This report has been produced as of the date hereof and the information herein may be subject to change. Maybank Kim Eng Research Pte. Ltd. ("Maybank KERPL") in Singapore has no obligation to update such information for any recipient. For distribution in Singapore, recipients of this report are to contact Maybank KERPL in Singapore in respect of any matters arising from, or in connection with, this report. If the recipient of this report is not an accredited investor, expert investor or institutional investor (as defined under Section 4A of the Singapore Securities and Futures Act), Maybank KERPL shall be legally liable for the contents of this report, with such liability being limited to the extent (if any) as permitted by law.

Thailand

Except as specifically permitted, no part of this presentation may be reproduced or distributed in any manner without the prior written permission of Maybank Kim Eng Securities (Thailand) Public Company Limited. Maybank Kim Eng Securities (Thailand) Public Company Limited ("MBKET") accepts no liability whatsoever for the actions of third parties in this respect.

Due to different characteristics, objectives and strategies of institutional and retail investors, the research products of MBKET Institutional and Retail Research departments may differ in either recommendation or target price, or both. MBKET reserves the rights to disseminate MBKET Retail Research reports to institutional investors who have requested to receive it. If you are an authorised recipient, you hereby tacitly acknowledge that the research reports from MBKET Retail Research are first produced in Thai and there is a time lag in the release of the translated English version.

The disclosure of the survey result of the Thai Institute of Directors Association ("IOD") regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information. The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey may be changed after that date. MBKET does not confirm nor certify the accuracy of such survey result.

The disclosure of the Anti-Corruption Progress Indicators of a listed company on the Stock Exchange of Thailand, which is assessed by Thaipat Institute, is made in order to comply with the policy and sustainable development plan for the listed companies of the Office of the Securities and Exchange Commission. Thaipat Institute made this assessment based on the information received from the listed company, as stipulated in the form for the assessment of Anti-corruption which refers to the Annual Registration Statement (Form 56-1), Annual Report (Form 56-2), or other relevant documents or reports of such listed company. The assessment result is therefore made from the perspective of Thaipat Institute that is a third party. It is not an assessment of operation and is not based on any inside information. Since this assessment is only the assessment result as of the date appearing in the assessment result, it may be changed after that date or when there is any change to the relevant information. Nevertheless, MBKET does not confirm, verify, or certify the accuracy and completeness of the assessment result.

US

This third-party research report is distributed in the United States ("US") to Major US Institutional Investors (as defined in Rule 15a-6 under the Securities Exchange Act of 1934, as amended) only by Maybank Kim Eng Securities USA Inc ("Maybank KESUSA"), a broker-dealer registered in the US (registered under Section 15 of the Securities Exchange Act of 1934, as amended). All responsibility for the distribution of this report by Maybank KESUSA in the US shall be borne by Maybank KESUSA. This report is not directed at you if MKE is prohibited or restricted by any legislation or regulation in any jurisdiction from making it available to you. You should satisfy yourself before reading it that Maybank KESUSA is permitted to provide research material concerning investments to you under relevant legislation and regulations. All U.S. persons receiving and/or accessing this report and wishing to effect transactions in any security mentioned within must do so with: Maybank Kim Eng Securities USA Inc. 400 Park Avenue, 11th Floor, New York, New York 10022, 1-(212) 688-8886 and not with, the issuer of this report.

UK

This document is being distributed by Maybank Kim Eng Securities (London) Ltd ("Maybank KESL") which is authorized and regulated, by the Financial Conduct Authority and is for Informational Purposes only. This document is not intended for distribution to anyone defined as a Retail Client under the Financial Services and Markets Act 2000 within the UK. Any inclusion of a third party link is for the recipients convenience only, and that the firm does not take any responsibility for its comments or accuracy, and that access to such links is at the individuals own risk. Nothing in this report should be considered as constituting legal, accounting or tax advice, and that for accurate guidance recipients should consult with their own independent tax advisers.

DISCLOSURES**Legal Entities Disclosures**

Malaysia: This report is issued and distributed in Malaysia by Maybank Investment Bank Berhad (15938- H) which is a Participating Organization of Bursa Malaysia Berhad and a holder of Capital Markets and Services License issued by the Securities Commission in Malaysia. **Singapore:** This report is distributed in Singapore by Maybank KERPL (Co. Reg No 198700034E) which is regulated by the Monetary Authority of Singapore. **Indonesia:** PT Maybank Kim Eng Securities ("PTMKES") (Reg. No. KEP-251/PM/1992) is a member of the Indonesia Stock Exchange and is regulated by the Financial Services Authority (Indonesia). **Thailand:** MBKET (Reg. No.0107545000314) is a member of the Stock Exchange of Thailand and is regulated by the Ministry of Finance and the Securities and Exchange Commission. **Philippines:** Maybank ATRKES (Reg. No.01-2004-00019) is a member of the Philippines Stock Exchange and is regulated by the Securities and Exchange Commission. **Vietnam:** Maybank Kim Eng Securities Limited (License Number: 117/GP-UBCK) is licensed under the State Securities Commission of Vietnam. **Hong Kong:** KESHK (Central Entity No AAD284) is regulated by the Securities and Futures Commission. **India:** Kim Eng Securities India Private Limited ("KESI") is a participant of the National Stock Exchange of India Limited and the Bombay Stock Exchange and is regulated by Securities and Exchange Board of India ("SEBI") (Reg. No. INZ000010538). KESI is also registered with SEBI as Category 1 Merchant Banker (Reg. No. INM 000011708) and as Research Analyst (Reg No: INH000000057) **US:** Maybank KESUSA is a member of/ and is authorized and regulated by the FINRA - Broker ID 27861. **UK:** Maybank KESL (Reg No 2377538) is authorized and regulated by the Financial Conduct Authority.

Disclosure of Interest

Malaysia: MKE and its Representatives may from time to time have positions or be materially interested in the securities referred to herein and may further act as market maker or may have assumed an underwriting commitment or deal with such securities and may also perform or seek to perform investment banking services, advisory and other services for or relating to those companies.

Singapore: As of 3 December 2021, Maybank KERPL and the covering analyst do not have any interest in any companies recommended in this research report.

Thailand: MBKET may have a business relationship with or may possibly be an issuer of derivative warrants on the securities /companies mentioned in the research report. Therefore, Investors should exercise their own judgment before making any investment decisions. MBKET, its associates, directors, connected parties and/or employees may from time to time have interests and/or underwriting commitments in the securities mentioned in this report.

Hong Kong: As of 3 December 2021, KESHK and the authoring analyst do not have any interest in any companies recommended in this research report.

India: As of 3 December 2021, and at the end of the month immediately preceding the date of publication of the research report, KESI, authoring analyst or their associate / relative does not hold any financial interest or any actual or beneficial ownership in any shares or having any conflict of interest in the subject companies except as otherwise disclosed in the research report.

In the past twelve months KESI and authoring analyst or their associate did not receive any compensation or other benefits from the subject companies or third party in connection with the research report on any account what so ever except as otherwise disclosed in the research report.

MKE may have, within the last three years, served as manager or co-manager of a public offering of securities for, or currently may make a primary market in issues of, any or all of the entities mentioned in this report or may be providing, or have provided within the previous 12 months, significant advice or investment services in relation to the investment concerned or a related investment and may receive compensation for the services provided from the companies covered in this report.

OTHERS**Analyst Certification of Independence**

The views expressed in this research report accurately reflect the analyst's personal views about any and all of the subject securities or issuers; and no part of the research analyst's compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.

Reminder

Structured securities are complex instruments, typically involve a high degree of risk and are intended for sale only to sophisticated investors who are capable of understanding and assuming the risks involved. The market value of any structured security may be affected by changes in economic, financial and political factors (including, but not limited to, spot and forward interest and exchange rates), time to maturity, market conditions and volatility and the credit quality of any issuer or reference issuer. Any investor interested in purchasing a structured product should conduct its own analysis of the product and consult with its own professional advisers as to the risks involved in making such a purchase.

No part of this material may be copied, photocopied or duplicated in any form by any means or redistributed without the prior consent of MKE.